The short answer: nobody can tell you, because no approval date exists. Eli Lilly's newest stated target for retatrutide is a filing target, "no later than the first quarter of 2027." Any approval date you see is someone's estimate.
The FDA's standard review clock runs about 12 months from submission. If Lilly files on time and the FDA uses that clock, a decision would land around early 2028. That's my arithmetic, not a date from Lilly or the FDA.
Status as of November 6, 2026: Retatrutide is not approved by the FDA or any regulator. Lilly has not announced that it has filed. TRIUMPH-5 has not reported. Nothing here is medical advice or a dosing guide.
Key takeaways
Lilly's filing target is Q1 2027, last stated October 8 in a court brief. It's a filing target, not an approval date.
The target moved once. Press reports expected a filing by the end of 2026, and on July 23 Lilly named Q1 2027, citing manufacturing data. It hasn't moved since.
Reasoning only: FDA's standard goal works out to about 12 months after submission, or roughly January to March 2028.
Four TRIUMPH trials have reported. At the 12 mg arm, average weight change ran -20.8% to -28.7% on the efficacy estimand and -18.8% to -25.0% on the treatment-regimen estimand (three trials).
TRIUMPH-5, the head-to-head against tirzepatide, has no results. Primary completion is estimated for November 2026.
Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.
When will reta be approved?
There's no date to quote. What follows is reasoning.
Under FDA's current goals, the review clock for a new drug or original biologic starts after a 60-day filing review. FDA then aims to act on 90 percent of standard applications "within 10 months of the 60-day filing date," and 90 percent of priority applications within 6 months (FDA PDUFA VII goals letter). That adds up to about 12 months or about 8 months from submission.
If Lilly submits in Q1 2027 and FDA accepts the filing | FDA goal date lands around |
|---|---|
Standard review | January to March 2028 |
Priority review | September to November 2027 |
Three limits on that table:
A goal date is a deadline to act, not a promise to approve. FDA can ask for more or say no.
It can slip. A major amendment "may extend the goal date by three months" (FDA). A late filing moves every date.
Priority isn't announced. None of Lilly's retatrutide statements cited here mention priority review or a voucher. Until one does, assume standard.
Retatrutide filing and approval timeline
Date | What happened | Source |
|---|---|---|
Dec 11, 2025 | First phase 3 readout, TRIUMPH-4 | |
May 21, 2026 | TRIUMPH-1 topline. No filing date in the release | |
July 23, 2026 | TRIUMPH-2 and -3 topline. Lilly names Q1 2027 | |
Aug 5, 2026 | On the Q2 call, Ricks says "submission by Q1 next year" | |
Sept 24, 2026 | Appeals court hears the drug-or-biologic case | |
Sept 29, 2026 | Lilly repeats: "plans to submit a Biologics License Application (BLA) in Q1 2027" | |
Oct 2, 2026 | FDA tells Lilly an application must go in as a drug | |
Oct 8, 2026 | Lilly tells the court it will file "no later than the first quarter of 2027" | |
Oct 28, 2026 | Beats Ozempic 2 mg in TRANSCEND-T2D-2. No filing date in the release | |
Nov 5, 2026 | Lilly previews knee data for ACR. No filing date | |
Q1 2027 | Planned filing | Target, not done |
Approval | No date from Lilly or FDA | Unknown |
Did Lilly push the reta filing back?
Yes, once, going by press reports. On July 23, BioSpace wrote that the filing was "pushed back from later this year" (BioSpace, July 23, 2026).
I couldn't verify that earlier target in Lilly's own words. Its May 21 and June 6 releases give no filing date. The first date from Lilly that I could confirm is Q1 2027.
The stated holdup is manufacturing, not trial results. Lilly said it "is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package" and "plans to subsequently submit retatrutide in Q1 2027" (Lilly, July 23, 2026). CEO Dave Ricks said on the August call that Lilly has "all the clinical data we need to submit, but we do need to gather a little bit more on the CMC side" (Q2 call transcript).
Nothing newer that I found moves it. Lilly's October 28 and November 5 releases give no filing date. Silence isn't a delay, but it makes the October 8 brief the newest explicit statement I could find.
Every TRIUMPH readout so far
Results are for the 12 mg arm unless noted. The next section explains the terms.
Trial | Who | Length | Result | Date | Source |
|---|---|---|---|---|---|
TRIUMPH-4 | 445 adults, obesity or overweight with knee osteoarthritis, no diabetes | 68 weeks | Weight: -28.7% efficacy, -23.7% treatment-regimen. Placebo: -2.1%, -4.6%. Knee pain score: -4.4 vs -2.4 placebo (efficacy) | Dec 11, 2025 | |
TRIUMPH-1 | 2,339 adults, obesity or overweight with a weight-related condition, no diabetes | 80 weeks | Weight: -28.3% efficacy, -25.0% treatment-regimen. Placebo: -2.2%, -3.9% | May 21, 2026; NEJM Sept 29 | |
TRIUMPH-1 knee group | 574 with knee osteoarthritis | 80 weeks | Pain score: -3.6 vs -1.9 placebo (hybrid). -4.1 vs -2.5 (ITT) | June 6, 2026; NEJM Sept 29 | |
TRIUMPH-1 sleep apnea | 243 with moderate-to-severe sleep apnea, no diabetes | 80 weeks | Breathing events per hour: -31.7 vs -9.9 placebo (hybrid) | June 6, 2026; NEJM Oct 21 | |
TRIUMPH-2 | 1,152 adults, type 2 diabetes with obesity or overweight | 80 weeks | Weight: -20.8% efficacy, -18.8% treatment-regimen. Placebo: -4.0%, -5.1%. A1C: -1.5 vs -0.2 points (efficacy) | July 23, 2026; Lancet Sept 29 | |
TRIUMPH-2 sleep apnea | 448 with moderate-to-severe sleep apnea and type 2 diabetes | 80 weeks | Breathing events per hour: -25.4 vs -10.3 placebo (hybrid) | NEJM Oct 21, 2026 | |
TRIUMPH-3 | 1,949 adults, BMI 35 or higher with established heart disease | 80 weeks | Weight: -22.6% efficacy. Placebo: -3.2%. No treatment-regimen figure in the release | July 23, 2026 | |
TRIUMPH-5 | About 800 adults with obesity, vs tirzepatide | 80 weeks to main result | No results | Pending |
Every trial above was Lilly-funded. I found no journal paper yet for TRIUMPH-3, and Lilly's detailed TRIUMPH-4 data is set for an ACR plenary on November 8 (Lilly, Nov 5, 2026). TRIUMPH-3 had too few heart events to settle anything (hazard ratio 0.82, range 0.55 to 1.22).
Get the filing date and the TRIUMPH-5 results when they land. Join the BHN newsletter.
Reta phase 3 results: which number is which?
Each trial gets counted more than one way. Those methods are called estimands.
Efficacy estimand. The headline number. It estimates what would've happened "had all randomized participants remained on study intervention" (Lilly, Sept 29, 2026).
Treatment-regimen estimand. The average effect "regardless of adherence" (Lilly, May 21, 2026). People who quit still count. NEJM calls this the intention-to-treat result for weight in TRIUMPH-1.
Hybrid estimand. Used for the knee and sleep apnea endpoints. It handles events "suggesting treatment failure" with a hypothetical strategy (NEJM).
The gap at 12 mg is 3.3 points in TRIUMPH-1, 2.0 in TRIUMPH-2 and 5.0 in TRIUMPH-4. Neither count is wrong. The 28.3% headline and NEJM's 25.0% are the same trial, and comparing either to another drug only works if both use the same method, which is why reta vs tirzepatide matches them. TRIUMPH-4 also ran 68 weeks, not 80.
Has TRIUMPH-5 reported?
No. On November 6 the registry listed it as active, not recruiting, with about 800 people, primary completion estimated for November 2026, study completion estimated for December 2026, and no results posted (ClinicalTrials.gov). The record was last updated July 20. Lilly called it "an ongoing Phase 3 trial" on October 28.
It doesn't look like it's holding up the filing. Lilly said in July it had "the clinical data package," before TRIUMPH-5 finished, and it counts four "global registrational trials" in the first TRIUMPH program. That's my reading, not Lilly's statement.
More Lilly trials run past the filing target, including TRIUMPH-7 (low back pain, estimated September 2027), TRIUMPH-6 (keeping weight off, April 2028) and TRIUMPH-Outcomes (heart and kidney outcomes, about 10,000 people, February 2029) (ClinicalTrials.gov).
Could the drug or biologic fight change the reta date?
Possibly the filing. Probably not the review clock.
Lilly wants a biologics license. FDA's October 2 letter says retatrutide "is not an analogous product to a protein" and an application "would need to be submitted under section 505," the drug route (FDA letter). The Seventh Circuit heard the appeal September 24, then ordered briefs on whether it has jurisdiction at all (court order). I found no ruling as of November 6.
Lilly told the court it "needs to know which application pathway (biological product or drug) to pursue when filing," and that more delay could force it "to choose between having retatrutide submitted when it is ready for patients and having it classified correctly" (Lilly brief, Oct 8, 2026). So the application type itself is unsettled.
The FDA goals above cover "NME NDA and original BLA submissions" with the same clock. My reasoning: the fight can move when Lilly files and what it files, but either route gets the same review goal. The money side is in how much does retatrutide cost.
Reta release date: can you get it before approval?
There's no release date. I found no launch date or price from Lilly, and approval doesn't set one. Right now the legal routes are narrow, and they're covered in can you legally get retatrutide, including expanded access.
When will reta be approved outside the US?
Unknown. Lilly says it has the data "to support global submissions" (Lilly, July 23, 2026), but the only quarter it has named is for the US. Retatrutide isn't on the European Medicines Agency's list of applications under evaluation, extracted October 5 (EMA, Oct 2026). I found no dated plan for other countries.
Retatrutide approval FAQ
Is retatrutide FDA approved yet?
No. Retatrutide is investigational and isn't approved by the FDA or any regulator. Lilly hasn't announced that it has filed.
Will reta be approved in 2027?
Nobody knows. FDA's standard goal points to early 2028 if Lilly files in Q1 2027. Only a priority review would put the goal date in 2027, and Lilly hasn't mentioned one in the statements cited here.
Did Lilly delay the retatrutide application?
Press reports expected a filing by the end of 2026. Lilly named Q1 2027 on July 23, citing its manufacturing data package, and has held that target since.
What were the retatrutide phase 3 results?
Average weight change at the 12 mg arm ran -20.8% to -28.7% on the efficacy estimand across four trials, and -18.8% to -25.0% on the treatment-regimen estimand in the three that reported one. The lowest figures came from people with type 2 diabetes.
Does Lilly need TRIUMPH-5 before it can file?
It doesn't appear so. Lilly said in July it had the clinical data package, and TRIUMPH-5 still has no results. That's a reading of Lilly's statements, not something Lilly has said directly.
Want the one-page version of what's approved, legal and tested? Get the free BHN cheat sheet.
Seen Lilly or the FDA say something newer? Reply and tell me, with the link.
Last updated November 6, 2026. This page is maintained. When Lilly files, TRIUMPH-5 reports or the court rules, a row changes here.